India pharma forecast to grow strongly in 2020
The rise in exports growth potential is believed to be in response to concerted reforms by the CDSCO and industry quality improvements in the last few years.
CPHI & P-MEC India – organised by Informa Markets – is set to open its doors to more than 43,000 attendees from 120 countries and 1,500 exhibitors, as new analysis shows a massive improvement in India’s global reputation. The India-specific findings of the CPHI Annual Report highlight the significant jumps made by the country in many categories.
India showed the largest gains in terms of ‘perceived growth potential’ and ‘biologics knowledge’, proving that industry efforts to align standards more closely with the US and Europe, as well as growth in biosimilars, have clearly been noted. But perhaps most significantly, these efforts are also being transferred into a reported increased confidence in outlook for 2020.
According to the Report, India is rated as having the second highest overall growth potential of any market globally. It also boasts the second-best score for ‘competitiveness’. A separate report by IBEF has found that Indian pharma companies are now forecast to see exports of $20 billion in 2020.
Survey respondents cited India’s ‘high-growth domestic market’ and ‘expanding manufacturing exports’ as the major drivers. The rise in exports growth potential is believed to be in response to concerted reforms by the Central Drugs Standard Control Organisation and industry quality improvements in the last few years.
Such was the confidence in India’s pharma market, the nation was ranked second for the ‘overall competitiveness’ of its pharma industry. India scored an average of 6.61 (out of ten), placing it behind only the US (7.03) and just above Germany (6.47).
With these hugely positive results as its backdrop, the 13th Annual CPHI & P-MEC India will take place in Delhi’s India Expo Centre. The event will be held in the nation’s capital and is designed to attract a wider international audience, helping more closely integrate vital regulatory pathways into event content, and allowing an even more diverse range of partnerships. Ultimately, this empowers attendees to meet with API suppliers, distributors, contract providers and machinery specialists all in one venue.
Cara Turner, Brand Director at Informa, said: “It’s such an exciting time to be working in India, with so many new opportunities now merging. This year looks set to see India’s biggest ever CPHI and that bodes extremely well for the wider industry in 2020.”
The Pre-Connect Congress and the daily series of Pharma Insight Briefings in the InnoPack Theatre will deliver topical analysis to keep the industry abreast of the biggest opportunities. The CEO Roundtable is expected to be another highlight of the event. This ‘closed door’ session will deliver the discussions and conclusions that help this market to enhance its position as a global superpower in the pharma world.
Encouragingly for deal-making at the event, the number of visitors and exhibitors signed up to take part in Live Pharma Connect the ‘Match and Meet’ service this year has doubled – meaning 2020 looks set to be a record-breaking year for pharma in India.
In addition, a key part of Indian Pharma Week is the ‘Women in Pharma’ Forum. Under the theme of ‘Women Empowers’, this event is designed to celebrate the influential contribution of women executives in the pharmaceutical industry. This event allows women to share their stories, experience and knowledge, as they help redefine and assert the leadership role women play.
Finally, P-MEC India is again playing a key role in helping this burgeoning market advance by supplying the latest technologies and machinery. Globally there has been a tremendous push to lower the cost of healthcare, with an increased use of generics and a commitment to lower manufacturing costs, improve process R&D and reduce waste. The net result of these changes is fundamentally shifting the tools we use to develop, test and manufacture the drugs of tomorrow.
“As the pharma industry looks increasingly towards India for high-quality, low-cost pharma solutions, CPHI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At the event you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business,” commented Rahul Deshpande Group Director at Informa.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...